Patents by Inventor Mike Elias Lizarzaburu

Mike Elias Lizarzaburu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20230052348
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 16, 2023
    Applicant: AMGEN INC.
    Inventors: Sean P BROWN, David Karl BEDKE, Michael R. DEGRAFFENREID, Jiasheng FU, Zhinghong LI, Felix GONZALEZ LOPEZ DE TURISO, Ana GONZALEZ BUENROSTRO, Michael W. GRIBBLE JR., Michael G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Mario G. CARDOZO, Alan C. CHENG
  • Compounds that inhibit MCL-1 protein
    Patent number: 11306107
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: April 19, 2022
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, David Karl Bedke, Michael R. Degraffenreid, Jiasheng Fu, Zhihong Li, Felix Gonzalez Lopez De Turiso, Ana Gonzalez Buenrostro, Michael W. Gribble, Jr., Michael G. Johnson, Todd J. Kohn, Kexue Li, Yunxiao Li, Mike Elias Lizarzaburu, Yosup Rew, Joshua Taygerly, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu, Manuel Zancanella, Xian Yun Jiao, Liusheng Zhu, Xianghong Wang, Julio C. Medina, Jason A. Duquette, Jonathan B. Houze, Marc Vimolratana, Mario G. Cardozo, Alan C. Cheng
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20210230189
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: February 24, 2017
    Publication date: July 29, 2021
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, David Karl BEDKE, Micheal R. DEGRAFFENREID, Jiasheng FU, Zhihong LI, Felix GONZALEZ LOPEZ TURISO, Ana GONZALEZ BUENROSTRO, Micheal W. GRIBBLE, JR., Micheal G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcal WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Marlo G. CARDOZO, Alan C. CHENG
  • Compounds that inhibit MCL-1 protein
    Patent number: 10836779
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: November 17, 2020
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Yunxiao Li, Mike Elias Lizarzaburu, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Ming Yu, Manuel Zancanella, Liusheng Zhu, Ana Gonzalez Buenrostro, Zhihong Li
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20200062780
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 13, 2019
    Publication date: February 27, 2020
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Compounds that inhibit Mcl-1 protein
    Patent number: 10494381
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: December 3, 2019
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Mike Elias Lizarzaburu, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20190023720
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 24, 2019
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S, LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20190016736
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 17, 2019
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Compounds that inhibit Mcl-1 protein
    Patent number: 10100063
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: October 16, 2018
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Yunxiao Li, Mike Elias Lizarzaburu, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Ming Yu, Manuel Zancanella, Liusheng Zhu, Ana Gonzalez Buenrostro, Zhihong Li
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20170088560
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: December 12, 2016
    Publication date: March 30, 2017
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20160068545
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: August 28, 2015
    Publication date: March 10, 2016
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc VIMOLRATANA, Xianghong Wang, Ming Yu, Manuel ZANCANELLA, Liusheng Zhu, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
    Patent number: 8785468
    Abstract: Provided herein are compounds of formula I: wherein A, B, X, R1, R2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: July 22, 2014
    Assignee: Amgen Inc.
    Inventors: Xiaohui Du, Zice Fu, Jonathan B. Houze, XianYun Jiao, Yong-Jae Kim, Leping Li, Jinqian Liu, Mike Elias Lizarzaburu, Julio C. Medina, Wang Shen, Simon Turcotte, Ming Yu
  • PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS
    Publication number: 20120115811
    Abstract: Provided herein are compounds of formula I: wherein A, B, X, R1, R2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions.
    Type: Application
    Filed: February 12, 2010
    Publication date: May 10, 2012
    Applicant: Amgen Inc.
    Inventors: Xiaohui Du, Zice Fu, Jonathan B. Houze, Xian Yun Jiao, Yong-Jae Kim, Leping Li, Jinqian Liu, Mike Elias Lizarzaburu, Julio C. Medina, Wang Shen, Simon Turcotte, Ming Yu